THE MANAGER of Baillie Gifford’s £350 million Edinburgh Worldwide Investment Trust feels that stock markets have settled down following the political shocks of 2016, with most companies now back to performing on an individual basis.

Douglas Brodie said that the “move away from a sentiment-led market backdrop” was of benefit to the trust, which made a net asset value return of 31.6 per cent in the year to the end of October against the S&P Global Small Cap Index’s growth of 13.4 per cent.

“We are not particularly surprised by this,” Mr Brodie added. “Stock market analysis has consistently shown that, in the longer term, company specific fundamentals ultimately prevail, hence our focus on stock selection and structural growth opportunities.”

Mr Brodie said that a diverse range of stocks had contributed to performance during the year under review, with biotechnology companies, online aggregators, e-commerce retailers and companies involved in digital manufacturing and software contributing to the trust’s growth.

At an individual stock level Mr Brodie said that American company Alnylam Pharmaceuticals made a significant contribution thanks to a positive trial from one of its drugs.

“This is the first example from its extensive drug pipeline to successfully navigate the clinical trials process and it significantly validates the core gene-silencing technology platform that underpins the business,” he said.

Mr Brodie also highlighted online lending exchange LendingTree and fibre-laser maker IPG Photonics as being significant contributors to returns.

As the trust’s main objective is to produce capital growth it is not paying a dividend for the year, although if underlying income increases it will look to make a minimum distribution in future.

This would be to maintain investment trust status as opposed to adopting an income strategy.